$CELZ — Regenerative Medicine Company with Multiple H1 2026 Catalysts

Creative Medical Technology Holdings is a clinical-stage biotech advancing stem cell-based therapies, currently trading around $2.17. Here's an overview of where things stand:

The Basics CELZ is developing regenerative treatments across immunology, endocrinology, urogynecology, and orthopedics. Its lead program, CELZ-201 (Olastrocel), is being evaluated for chronic lower back pain and Type 1 diabetes.

Key Catalysts

* FDA Fast Track designation secured for CELZ-201-DDT (degenerative disc disease)
* Interim ADAPT trial data showed statistically significant improvements in pain and function - independent DSMB found no serious adverse events
* Topline ADAPT results and early Type 1 diabetes data both expected H1 2026
* April 2026: Ultrasome pilot study reported a 93% responder rate in knee osteoarthritis -extending the CELZ-201 platform into a cell-free, scalable format
* WHO has assigned International Nonproprietary Names to two separate programs (olastrocel and etaroleucel) - a notable regulatory milestone for a company of this size
* 60+ patents, 6B+ clinical-grade cells manufactured